Related Experiment Video
Updated: Jan 17, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and
Tianxing Liu1, Lingyu Ke1, Ruize Sun1
1Natural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland, BT71NN, UK.
Abstract:
Antibody-drug conjugates (ADCs) have transformed cancer therapy but remain limited by their dependence on internalizing antigens, poor applicability to untargetable tumors, and susceptibility to drug resistance. Therefore, a modular antimicrobial-peptide (AMP)-based therapeutic system centered on a rationally designed conjugate, 270, is presented, which integrates three optimized components: a selectivity-enhanced AMP core via a membrane affinity reconstruction strategy, a conformation-driven polyethylene glycolylated blocker to minimize off-target effects, and an N-terminal cap to improve stability in human serum. By targeting nonendocytic membrane surface receptors via small-molecule ligands, conjugate 270 exhibits potent and selective cytotoxicity against target tumor cells, effectively eliminating the majority of tumor cells within a few hours. Meanwhile, it exhibits high serum stability, minimal hemolysis, and negligible cytotoxicity toward normal cells at therapeutic concentrations. Mechanistic studies confirm ligand-dependent membrane localization, rapid depolarization, and disruption, along with mitochondrial dysfunction. Moreover, it demonstrates significant therapeutic efficacy against four cell lines resistant to conventional chemotherapeutic agents. While additional in vivo validation is warranted, this work lays the foundation for a flexible AMP-based approach to address untargetable and drug-resistant cancers.
Insights
A novel antimicrobial peptide (AMP)-based conjugate, 270, offers a new therapeutic strategy for untargetable and drug-resistant cancers by targeting membrane surface receptors, showing potent tumor cell killing with minimal side effects.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Antibody-drug conjugates (ADCs) are limited by antigen dependence and drug resistance.
- Untargetable tumors and acquired resistance pose significant challenges in cancer therapy.
Purpose of the Study:
- To develop a modular antimicrobial peptide (AMP)-based therapeutic system (conjugate 270) for cancers.
- To overcome limitations of current cancer therapies, including resistance and targeting difficulties.
Main Methods:
- Designed conjugate 270 integrating a selectivity-enhanced AMP core, a polyethylene glycolylated blocker, and an N-terminal cap.
- Targeted nonendocytic membrane surface receptors using small-molecule ligands.
- Evaluated cytotoxicity, serum stability, hemolysis, and therapeutic efficacy against resistant cell lines.
Main Results:
- Conjugate 270 demonstrated potent and selective cytotoxicity against target tumor cells, eliminating most within hours.
- The system showed high serum stability, minimal hemolysis, and negligible toxicity to normal cells.
- Significant efficacy was observed against cancer cell lines resistant to conventional chemotherapeutics.
Conclusions:
- Conjugate 270 represents a flexible AMP-based approach for treating untargetable and drug-resistant cancers.
- The modular design allows targeting of membrane surface receptors, bypassing internalization requirements.
- Further in vivo studies are needed to validate its therapeutic potential.
